MAP2K7 and neoplasm: However, systematic data comparing BRAFV600E lines are generally lacking, and it is not known whether adaptation to different MEK and RAF inhibitors is fundamentally similar or whether multiple adaptive mechanisms are active in a single cell line or tumor.